BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:stapokibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of stapokibart\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07678931-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:stapokibart: Phase 3 readout est. (NCT07678931)
DESCRIPTION:stapokibart\, phase 3.\nStudy: Study on the Treatment of Adoles
 cent Patients With Seasonal Allergic Rhinitis\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sta
 pokibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07678931
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073664-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:stapokibart: Phase na readout est. (NCT07073664)
DESCRIPTION:stapokibart\, phase na.\nStudy: A Study Evaluating the Efficacy
  of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) Combined With
  Stapokibart in the Treatment of Type 2 Chronic Rhinosinusitis\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/stapokibart#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07073664
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143864-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:stapokibart: Phase na readout est. (NCT07143864)
DESCRIPTION:stapokibart\, phase na.\nStudy: Efficacy and Safety of Stapokib
 art for Primary Cutaneous Amyloidosis\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokib
 art#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07143864
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07240376-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:stapokibart: Phase na readout est. (NCT07240376)
DESCRIPTION:stapokibart\, phase na.\nStudy: Efficacy and Safety of Stapokib
 art in Non-Allergic Rhinitis With Eosinophilia Syndrome\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07240376
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040072-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:stapokibart: Phase 1 readout est. (NCT07040072)
DESCRIPTION:stapokibart\, phase 1.\nStudy: Finotonlimab Combined With Stapo
 kibart in the Treatment of Recurrent/Metastatic HNSCC\nEstimated primary c
 ompletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /stapokibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07040072
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210554-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:stapokibart: Phase 3 readout est. (NCT07210554)
DESCRIPTION:stapokibart\, phase 3.\nStudy: Study of Stapokibart Injection i
 n Subjects With Moderate to Severe Bullous Pemphigoid\nEstimated primary c
 ompletion: 27 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07210554
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791615-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:stapokibart: Phase 2 readout est. (NCT07791615)
DESCRIPTION:stapokibart\, phase 2.\nStudy: A Phase II Study of Stapokibart 
 Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma
 \nEstimated primary completion: June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/stapokibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07791615
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616609-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:stapokibart: Phase na readout est. (NCT07616609)
DESCRIPTION:stapokibart\, phase na.\nStudy: Preoperative Stapokibart for En
 doscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/stapokibart#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07616609
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547333-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20320429
DTEND;VALUE=DATE:20320430
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT06547333)
DESCRIPTION:stapokibart\, phase 2/3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study of CM310 in Subjects With Moderate to Severe Chronic Obs
 tructive Pulmonary Disease\nEstimated primary completion: 29 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06547333
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761028-1335@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT05761028)
DESCRIPTION:stapokibart\, phase 2/3\, Asthma.\nStudy: A Study of CM310 in S
 ubjects With Moderate to Severe Asthma\nEstimated primary completion: May 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576102
 8
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
